Case Reports - Oncology
Vol. 86 No. 3 (2014)
https://doi.org/10.4081/aiua.2014.3.227

Localised prostate cancer and hemophilia A (AHA): Case report and management of the disease

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 10 October 2014
Published: 30 September 2014
2289
Views
1452
Downloads
Activated partial thromboplastin time, Factor VIII, Hemophilia A, Prostate cancer, Radical prostatectomy

Authors

Francesco Celestino
frapichi@libero.it
Urologic Oncology Unit, Policlinico Casilino, Rome, Italy.
Cristian Verri
Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Francesco De Carlo
Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Savino Mauro Di Stasi
Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy.
Acquired Hemophilia A (AHA) is a rare bleeding diathesis characterized by the development of autoantibodies against factor VIII (FVIII). About half of the cases are idiopathic and the other half are associated with autoimmune diseases, postpartum problems, infections, inflammatory bowel disease, drugs, lymphoproliferative disorders or solid tumors . AHA is associated with malignancies in 7-15% of cases. We report a case of AHA in a 65 year old patient with prostatic carcinoma, who underwent retropubic radical prostatectomy (RP).

Downloads

Download data is not yet available.

How to Cite



Localised prostate cancer and hemophilia A (AHA): Case report and management of the disease. (2014). Archivio Italiano Di Urologia E Andrologia, 86(3), 227-228. https://doi.org/10.4081/aiua.2014.3.227

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.